SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-155116
Filing Date
2024-06-05
Accepted
2024-06-05 16:02:00
Documents
14
Period of Report
2024-06-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d805683d8k.htm   iXBRL 8-K 40111
2 EX-3.1 d805683dex31.htm EX-3.1 7941
  Complete submission text file 0001193125-24-155116.txt   177528

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cogt-20240605.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20240605_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20240605_pre.xml EX-101.PRE 11710
17 EXTRACTED XBRL INSTANCE DOCUMENT d805683d8k_htm.xml XML 3832
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 241021924
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)